Search results for "interferon"

showing 10 items of 963 documents

Expansion of intracellular IFN-γ positive lymphocytes during Mycoplasma agalactiae infection in sheep.

2010

Abstract A method to assess the expansion of antigen-specific intracellular IFN-γ positive T cell subsets during the infection will be helpful for a better understanding of mycoplasmal infections physiopathology in the sheep. We analysed the percentage of antigen-specific lymphocytes positive for intracellular IFN-γ during the infection of sheep with Mycoplasma agalactiae by culturing peripheral blood mononuclear cells of infected or uninfected animals with irradiated M. agalactiae . The expansion of antigen-specific IFN-γ positive lymphocytes in infected sheep was initially sustained by CD4 + T cells at day 15 after infection, when antigen specific IgG start to be detectable, followed by C…

Mycoplasma agalactiaeT cellved/biology.organism_classification_rank.speciesDouble negativeSheep DiseasesBiologyPeripheral blood mononuclear cellMycoplasma agalactiaeInterferon-gammaImmunityAntibody SpecificitymedicineCytotoxic T cellAnimalsMycoplasma InfectionsLymphocytesAgalactia Mastitis T cells Peripheral blood mononuclear cells CD4+ cells CD8+ cellsAntigens BacterialSheepGeneral Veterinaryved/biologyAntibodies Bacterialmedicine.anatomical_structureImmunoglobulin GImmunologyLeukocytes MononuclearIntracellularCD8Research in veterinary science
researchProduct

The suppressive effects of recombinant human tumor necrosis factor‐alpha on normal and malignant myelopoiesis: Synergism with interferon‐gamma

1988

The modulation of growth of normal and leukemic myeloid progenitor cells in soft agar cultures by recombinant human tumor necrosis factor-alpha (TNF alpha) and recombinant human interferon-gamma (IFN gamma) was investigated. TNF alpha inhibited colony formation of all colony types representing different maturational stages of normal progenitor cells committed to the myeloid lineage with different orders of sensitivity. Blast-type colonies derived from patients with acute myelogenous leukemia were more sensitive to TNF alpha inhibition than progenitor cells purified from normal bone marrow or bone marrow from patients with stable-phase chronic myelogenous leukemia. The response of most colon…

MyeloidBone Marrow CellsBiologyInterferon-gammaBone MarrowmedicineHumansInterferon gammaProgenitor cellTumor Necrosis Factor-alphaAntibodies MonoclonalDrug SynergismCell BiologyHematopoietic Stem Cellsmedicine.diseaseRecombinant ProteinsLeukemia Myeloid AcuteLeukemiamedicine.anatomical_structureLeukemia MyeloidImmunologyCancer researchTumor necrosis factor alphaBone marrowMyelopoiesisChronic myelogenous leukemiamedicine.drugThe International Journal of Cell Cloning
researchProduct

CXCR3-ligand-mediated skin inflammation in cutaneous lichenoid graft-versus-host disease.

2007

Background Lichenoid graft-versus-host disease (liGVHD) histologically shares several common features with other lichenoid dermatoses, such as cutaneous lupus erythematosus and lichen planus (LP), which collectively show a junctional infiltrate of cytotoxic lymphocytes with liquefaction of the basal layer ("interface dermatitis"). Because recent studies have shown a role for type I interferon (IFN)–associated inflammation, including lymphocyte recruitment via CXCR3 ligand interaction in cutaneous lupus erythematosus and LP, we hypothesized that similar mechanisms might also be involved in liGVHD. Methods Ten representative lesional skin biopsies taken from patients with different subsets of…

Myxovirus Resistance ProteinsChemokinePathologymedicine.medical_specialtyLichenoid EruptionsReceptors CXCR3CD3T-LymphocytesGraft vs Host DiseaseInflammationDermatitisDermatologyIn situ hybridizationCXCR3LigandsChemokine CXCL9Skin DiseasesGTP-Binding ProteinsMedicineCXCL10HumansLymphocytesRNA MessengerIn Situ Hybridizationbiologybusiness.industryLichen PlanusInterferon-alphaChemokine CXCL10stomatognathic diseasesImmunologyChronic DiseaseInterferon Type Ibiology.proteinCXCL9Immunohistochemistrymedicine.symptomEpidermisbusinessJournal of the American Academy of Dermatology
researchProduct

Interferon-alpha inhibits hepatitis C virus subgenomic RNA replication by an MxA-independent pathway.

2001

Hepatitis C virus (HCV) persists in the majority of infected individuals and is a major cause of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. Chronic hepatitis C is currently treated with interferon (IFN)-α or with a combination of IFN-α and ribavirin. The availability of an HCV replicon system (Lohmann et al., Science 285, 110–113, 1999) allowed the investigation of the effects of IFN on genuine HCV replication in cultured cells. It is shown here that IFN-α inhibits subgenomic HCV RNA replication in HuH-7 human hepatoma cells. Immunofluorescence, Western blot and Northern blot analysis revealed that levels of both HCV protein and replicon RNA were reduced after treatme…

Myxovirus Resistance ProteinsHepatitis C virusHepacivirusBiologyViral Nonstructural Proteinsmedicine.disease_causeAntiviral Agentschemistry.chemical_compoundInterferonGTP-Binding ProteinsVirologymedicineTumor Cells CulturedHumansRepliconNorthern blotSubgenomic mRNADose-Response Relationship DrugRibavirinvirus diseasesRNAInterferon-alphaProteinsVirologyMolecular biologydigestive system diseasesNS2-3 proteasechemistryRNA ViralRepliconmedicine.drugThe Journal of general virology
researchProduct

Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

2014

International audience; The immune system is routinely confronted with cell death resulting from the physiological turnover of renewable tissues, as well as from pathological insults of several types. We hypothesize the existence of a mechanism that allows the immune system to discriminate between physiological and pathological instances of cell death, but the factors that determine whether cellular demise is perceived as a neutral, tolerogenic or immunogenic event remain unclear 1. Infectious insults are accompanied by so-called microbe-associated molecular patterns (MAMPs), i.e., viral or bacterial products that activate immune cells through a panel of pattern-recognition receptors (PRRs)…

Myxovirus Resistance ProteinsMessengerReceptor Interferon alpha-betaInbred C57BLchemotherapyInterferon alpha-betaMiceInterferonReceptorsAnthracyclinesNeoplasm MetastasisRIG-IPattern recognition receptorAdaptor ProteinsGeneral MedicineNeoadjuvant Therapy3. Good healthGene Expression Regulation NeoplasticTreatment OutcomeReceptors Pattern RecognitionInterferon Type I[SDV.IMM]Life Sciences [q-bio]/ImmunologyFemaleImmunocompetencemedicine.drugReceptorSignal TransductionBreast Neoplasms[SDV.CAN]Life Sciences [q-bio]/CancerBiologyPattern RecognitionSettore BIO/09General Biochemistry Genetics and Molecular BiologyParacrine signallingImmune systemmedicineCXCL10AnimalsHumanscancerRNA MessengerAutocrine signallingNeoplastic[SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/ImmunotherapyToll-Like Receptor 3Mice Inbred C57BLVesicular TransportChemokine CXCL10Adaptor Proteins Vesicular TransportGene Expression RegulationDoxorubicinImmunologyTLR3RNAAdaptor Proteins Vesicular Transport; Animals; Anthracyclines; Breast Neoplasms; Chemokine CXCL10; Doxorubicin; Female; Gene Expression Regulation Neoplastic; Humans; Immunocompetence; Interferon Type I; Mice Inbred C57BL; Myxovirus Resistance Proteins; Neoadjuvant Therapy; Neoplasm Metastasis; RNA; RNA Messenger; Receptor Interferon alpha-beta; Receptors Pattern Recognition; Toll-Like Receptor 3; Treatment Outcome; Signal Transduction
researchProduct

Correlation between clinical response and urinary interleukin levels using different doses and intravesical administration schedules of interferon-al…

1993

A total of 62 patients at high risk for recurrence of superficial bladder cancer were selected for a study designed to compare the prophylactic efficacy of different doses and schedules of sequential intravesical instillations of epirubicin and interferon-alpha-2b and to evaluate which sequence could enhance the release of cytokines in the urine. Our investigations showed a significant increase in urinary concentrations of interleukins in patients who received the sequential intravesical administration of epirubicin and interferon-alpha-2b. Higher urinary concentrations of interleukins and a lower recurrence rate were detected in patients who received interferon-alpha-2b 24 h after epirubic…

Nephrologymedicine.medical_specialtyUrologyUrinary systemUrologyAlpha interferonIntravesical immunotherapyUrineInterferon alpha-2PharmacologyDrug Administration ScheduleIntravesical chemotherapyInterferon-alpha-2bSettore MED/24 - UrologiaInternal medicinemedicineHumansCombined Modality TherapyEpirubicinbusiness.industryInterleukinsInterferon-alphaInterleukinCombined Modality TherapyRecombinant ProteinsClinical trialInterleukins (urinary concentration of)Administration IntravesicalUrinary Bladder NeoplasmsInterleukin-2Interleukin-4Neoplasm Recurrence LocalbusinessInterleukin-1Epirubicinmedicine.drugUrological Research
researchProduct

Non-eosinophilic Airway Hyper-reactivity in Mice, Induced by IFN-γProducing CD4+and CD8+Lung T cells, is Responsive to Steroid Treatment

2014

Non-eosinophilic asthma is characterized by infiltration of neutrophils into the lung and variable responsiveness to glucocorticoids. The pathophysiological mechanisms have not been characterized in detail. Here, we present an experimental asthma model in mice associated with non-eosinophilic airway inflammation and airway hyper-responsiveness (AHR). For this, BALB/c mice were sensitized by biolistic DNA immunization with a plasmid encoding the model antigen β-galactosidase (pFascin-βGal mice). For comparison, eosinophilic airway inflammation was induced by subcutaneous injection of βGal protein (βGal mice). Intranasal challenge of mice in both groups induced AHR to a comparable extent as w…

NeutrophilsImmunologyInflammationBiologyLymphocyte ActivationDexamethasoneLymphocyte DepletionInterferon-gammaMiceTh2 CellsAntigenmedicineAnimalsLungDexamethasoneMice Inbred BALB CLungDNAGeneral MedicineBiolisticsTh1 Cellsrespiratory systembeta-Galactosidasemedicine.diseaseAsthmaNeutrophiliarespiratory tract diseasesEosinophilsDisease Models Animalmedicine.anatomical_structureNeutrophil InfiltrationImmunologyTh17 CellsFemaleGoblet Cellsmedicine.symptomBronchoalveolar Lavage FluidInfiltration (medical)CD8GlucocorticoidT-Lymphocytes Cytotoxicmedicine.drugScandinavian Journal of Immunology
researchProduct

Vinblastine and interferon-alpha-2a regimen in the treatment of metastatic renal cell carcinoma.

1990

Thirteen patients with histologically proven advanced and/or metastatic renal cell carcinoma (RCC) were treated with vinblastine (Velbe, Eli Lilly, Sesto Fiorentino, Italy) and interferon-alpha-2a (Roferon-A, Roche, Milan). Eleven out of 13 patients were evaluable. Eighteen percent of patients had partial response, 46 % stable disease (SD), and 36 % progressive disease (PD). The mean survival of responders was 228+ days, whereas the patients showing SD and PD had a mean survival of 154+ and 107+ days respectively. Toxicity, including influenza-like syndrome, fever, neurological and gastrointestinal side effects, was generally mild. However, medication with paracetamol was required in 82 % …

OncologyAdultMaleCancer Researchmedicine.medical_specialtyInterferon alpha-2VinblastineGastroenterology03 medical and health sciences0302 clinical medicineStable DiseaseRenal cell carcinomaPartial responseInternal medicinemedicineHumans030212 general & internal medicineInterferon Alpha 2aCarcinoma Renal CellAgedbusiness.industryInterferon-alphaGeneral MedicineMiddle Agedmedicine.diseaseKidney NeoplasmsRecombinant ProteinsVinblastineRegimenOncology030220 oncology & carcinogenesisToxicityInterferon Type IDrug Therapy CombinationFemalebusinessProgressive diseasemedicine.drugTumori
researchProduct

Epidoxorubicin and double biochemical 5-fluorouracil modulation with folinic acid and human lymphoblastoid interferon in advanced gastric carcinoma: …

1996

In our previous randomized trial of advanced gastric cancer patients, the addition of epirubicin (EPI) to 5-fluorouracil (FU) with folinic acid (FA) resulted in an improved response rate and survival in the responder patients. Preclinical studies also showed an enhancement of FU and anthracyclines with interferon. To evaluate the possibility of human lymphoblastoid interferon (IFN) to enhance the therapeutic activity of the FA-FU + EPI combination regimen, 39 advanced gastric cancer patients received: FU at 375 mg/m2 i.v. immediately after FA (l-isomer form) at 100 mg/m2 i.v. for 5 consecutive days; EPI at 60 mg/m2 i.v. on day 1, and IFN 3 MU s.c. for 7 consecutive days, starting 2 days bef…

OncologyAdultMaleCancer Researchmedicine.medical_specialtymedicine.medical_treatmentLeucovorinPhases of clinical researchFolinic acidStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineCarcinomaHumansAgedEpirubicinNeoplasm StagingChemotherapybusiness.industryPatient SelectionInterferon-alphaGeneral MedicineMiddle Agedmedicine.diseaseCombined Modality TherapySurvival RateRegimenOncologyFluorouracilToxicityFemaleFluorouracilbusinessmedicine.drugEpirubicinOncology
researchProduct

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

2003

Imatinib, a selective inhibitor of the BCR-ABL tyrosine kinase, produces high response rates in patients with chronic-phase chronic myeloid leukemia (CML) who have had no response to interferon alfa. We compared the efficacy of imatinib with that of interferon alfa combined with low-dose cytarabine in newly diagnosed chronic-phase CML.We randomly assigned 1106 patients to receive imatinib (553 patients) or interferon alfa plus low-dose cytarabine (553 patients). Crossover to the alternative group was allowed if stringent criteria defining treatment failure or intolerance were met. Patients were evaluated for hematologic and cytogenetic responses, toxic effects, and rates of progression.Afte…

OncologyAdultMalemedicine.medical_specialtyAdolescentAlpha interferonAntineoplastic AgentsPiperazineschemistry.chemical_compoundhemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective StudiesInterferon alfaAgedbusiness.industryPonatinibCytarabineInterferon-alphaImatinibGeneral MedicineMiddle AgedDasatinibSurvival RateImatinib mesylatePyrimidineschemistryNilotinibImmunologyBenzamidesLeukemia Myeloid Chronic-PhaseCytarabineDisease ProgressionImatinib MesylateFemalebusinessmedicine.drugThe New England journal of medicine
researchProduct